Inhaled Therapy with Ensifentrine Significantly may Reduce COPD Exacerbations, unravels research

The pooled analysis included a total of 975 patients treated with ensifentrine and 574 who received placebo. Also, 62% of participants were also using either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA), while 18% were on inhaled corticosteroids.

These results showed a 41% reduction in the rate of moderate to severe exacerbations among patients taking ensifentrine when compared to the placebo group (rate ratio: 0.59, 95% confidence interval [CI]: 0.43-0.80; p < .001). Similarly, the risk of experiencing an exacerbation was also reduced by 41% (hazard ratio: 0.59, 95% CI: 0.44-0.81; p < .001).

The study further revealed that the benefits of ensifentrine extended across multiple patient subgroups, regardless of age, sex, race, disease severity, history of exacerbations, eosinophil count, or background COPD medication use.

This data suggested that ensifentrine may help delay progression of patients from infrequent exacerbators (Global Initiative for Chronic Obstructive Lung Disease Group B) to frequent exacerbators (Group E), indicating a potential role in slowing disease progression. Overall, these findings underline the potential of ensifentrine as a strong addition to COPD management, addressing the urgent need for therapies that reduce exacerbation rates and improve long-term outcomes.

Reference:

Sciurba, F. C., Christenson, S. A., Rheault, T., Bengtsson, T., Rickard, K., & Barjaktarevic, I. Z. (2025). Effect of dual phosphodiesterase 3 and 4 inhibitor ensifentrine on exacerbation rate and risk in patients with moderate to severe COPD. Chest, 167(2), 425–435. https://doi.org/10.1016/j.chest.2024.07.168